The FDA has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA).

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

With the potential for pharmaceutical import tariffs spurring a rush of life sciences investments in the U.S., AbbVie is ...

AbbVie wins FDA approval for Rinvoq in giant cell arteritis after strong Phase 3 results and a 57.2% year-over-year sales ...

AbbVie is a popular stock with dividend investors for its high starting yield and continuous dividend increases. AbbVie is a ...

Shares of AbbVie Inc. rose 3.38% to $192.34 Monday, on what proved to be an all-around great trading session for the stock ...

Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, ...

AbbVie (NYSE:ABBV), a biopharmaceutical company, is engaged in the research and development, manufacture, commercialization, ...

AbbVie has become the latest pharma group to make a big capital investment announcement in the US and court favour with the ...

All U.S. service members aboard the USS Harry S. Truman have been accounted for and are safe after a fighter jet, an F/A-18E ...

AbbVie Inc. raised its profit outlook for the year on better-than-expected sales from newer autoimmune treatments.

The analyst continues to be positive on AbbVie, as he maintained his outperform (buy, in other words) recommendation on the stock and $215 per-share price target. Not surprisingly, according to ...